Vγ2 x PD-L1, a Bispecific Antibody Targeting Both the Vγ2 TCR and PD-L1, Improves the Anti-Tumor Response of Vγ2Vδ2 T Cell
Rui Yang(Wuhan YZY Biopharma (China)), Pengfei Zhou(First Affiliated Hospital of Henan University of Traditional Chinese Medicine)
Cited by 10
Related Papers
Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors
|Journal of Hematology & Oncology|2022|178